Metastases to bone are a common site of cancer recurrence for many types of solid tumors. Bone metastases cause substantial morbidity, including fractures, spinal cord compression, the need for surgery or radiation therapy to the bone for a symptomatic metastasis, and hypercalcemia of malignancy. Osteoclast inhibitors such as bisphosphonates and Denosumab (RANKL inhibitor) significantly reduce the frequency of skeletal-related events (SREs) in patients with bone metastases from a wide variety of cancer types.
The benefits of osteoclast inhibitors in patients with bone metastases from solid tumors will be presented here. The use of bisphosphonates in patients with multiple myeloma, the use of osteoclast inhibitors for patients with bone loss related to cancer treatment (eg, aromatase inhibitors for breast cancer and androgen deprivation therapy for prostate cancer), the use of osteoclast…
